From a cancer‐immunologic point of view, it would be of high relevance to identify the distinct immune signatures associated with non‐CRP response and IO treatment failure to identify potential targets for tailored combination therapy in this immunotherapy‐unresponsive RCC subgroup. The gene discussed is CRP; the disease is cancer.